Patient-derived PDX and organoid models reveal distinct molecular mechanisms of acquired resistance to olaparib and enfortumab vedotin in genitourinary cancers. (EORTC-NCI-AACR 2026) - Sep 11, 2026 - Abstract #152; PB-152; Pres time: Nov 18, 2026; Location: Exhibition Hall; "Abstract will be available as of 4 November (with consent of the author)"
Clinical • Preclinical • Genito-urinary Cancer • Oncology • Solid Tumor
|